Daniel P. Shook

Array ( [id] => 18762892 [patent_doc_number] => 11813271 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Sialic acid compositions for the use of inhibiting and treating coronavirus infection [patent_app_type] => utility [patent_app_number] => 17/916104 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7960 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16961541 [patent_doc_number] => 20210213040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE [patent_app_type] => utility [patent_app_number] => 17/213567 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434321 [patent_doc_number] => 20230181615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES [patent_app_type] => utility [patent_app_number] => 17/912933 [patent_app_country] => US [patent_app_date] => 2021-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004942 [patent_doc_number] => 20220363708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/207161 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17207161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258464 [patent_doc_number] => 20210371449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/206896 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37267 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468796 [patent_doc_number] => 20230203078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/912418 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18319629 [patent_doc_number] => 20230117757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => COENZYME Q PRODUCTION ACCELERATOR AND METHOD FOR ACCELERATING COENZYME Q PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/906194 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19883025 [patent_doc_number] => 12268707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Treatment for coronavirus infection and associated cytokine toxicity [patent_app_type] => utility [patent_app_number] => 17/910220 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 11502 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18320874 [patent_doc_number] => 20230119002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES AND CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/905210 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310380 [patent_doc_number] => 20230114280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/905262 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345004 [patent_doc_number] => 20230133114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/905074 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328201 [patent_doc_number] => 11633416 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-04-25 [patent_title] => Oral formulations of CD73 compounds [patent_app_type] => utility [patent_app_number] => 17/193473 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18579 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 223 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16898890 [patent_doc_number] => 20210177806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => COMBINATION PHARMACEUTICAL, PROPHYLACTIC OR SUPPRESSIVE AGENT FOR DEVELOPMENT OF RESISTANCE TO PYRIMIDINE ANTIMETABOLITE, AND METHOD OF TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/188129 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18267905 [patent_doc_number] => 20230089147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS [patent_app_type] => utility [patent_app_number] => 17/904536 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990185 [patent_doc_number] => 20210228605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME [patent_app_type] => utility [patent_app_number] => 17/184369 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725790 [patent_doc_number] => 20230340008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME [patent_app_type] => utility [patent_app_number] => 17/791799 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 288 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140151 [patent_doc_number] => 20210308162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 17/174018 [patent_app_country] => US [patent_app_date] => 2021-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868469 [patent_doc_number] => 20210161936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) [patent_app_type] => utility [patent_app_number] => 17/171548 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18259736 [patent_doc_number] => 11607422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-21 [patent_title] => Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma [patent_app_type] => utility [patent_app_number] => 17/161928 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 61 [patent_no_of_words] => 14271 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18280112 [patent_doc_number] => 20230095584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => PROCESS OF PREPARING NUCLEIC ACID OLIGOMER [patent_app_type] => utility [patent_app_number] => 17/792484 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792484 [rel_patent_id] =>[rel_patent_doc_number] =>)